Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
US FDA Doesn’t Want ANDAs With Facilities Not Ready For Inspection Even Though It Can Accept Them
May 04 2023
•
By
Derrick Gingery
One of the priorities in GDUFA III is to reduce the number of assessment cycles needed to gain approval. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
More from Generics
More from Biosimilars & Generics